Avastin (bevacizumab) is a humanized monoclonal antibody with evident antiangiogenic activity, which blocks vessel endothelial growth factor (VEGF) and prevent its binding with receptors. Chronologically Avastin was among the first (second after trastuzumab) targeted agents approved for clinical practice. Also it is the only targeted agent used in the main malignant solid tumor types: metastatic colorectal cancer, locally recurrent or metastatic breast cancer, metastatic or recurrent nonsquamous non-small cell lung cancer, advanced and/or metastatic renal cell cancer, glioblastoma (stage IV glioma according to WHO classification) and epithelial ovarian, fallopian tube, or primary peritoneal cancer. Therefore Avastin can be defined today as the first and the best, because not one targeted agent has so wide clinical use and indications in practical oncology and moreover practically there were no ineffective clinical trials with Avastin. Also it is necessary to mention that large clinical experience with Avastin demonstrates comparative safety of the agent in different patient’s subgroups and populations.